NCT02609022 - Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions

Myasthenia Gravis

Interventions

BIOLOGICAL

CV-MG01

"3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.~Two dose levels: low and high dose."

BIOLOGICAL

Placebo

3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.

Trial Locations (1)

2650

University Hospital, Antwerp, Edegem